Published in Antimicrob Agents Chemother on October 01, 1992
Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev (1995) 1.73
Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol (2009) 1.70
Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care (2002) 1.61
Role of endotoxin in the pathogenesis of critical illness polyneuropathy. J Neurol (2008) 1.39
Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles. J Immunol (2011) 1.25
Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 1.05
Endotoxemia and endotoxin tolerance in patients with ARDS. Langenbecks Arch Surg (2008) 1.04
Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect. Toxins (Basel) (2013) 0.98
Does gram-negative bacteraemia occur without endotoxaemia? A meta-analysis using hierarchical summary ROC curves. Eur J Clin Microbiol Infect Dis (2009) 0.84
Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen. J Biol Chem (2014) 0.77
In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G. Antimicrob Agents Chemother (1997) 0.75
IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A Before-After Cohort Study. PLoS One (2016) 0.75
APACHE II: a severity of disease classification system. Crit Care Med (1985) 69.83
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet (1988) 2.67
Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med (1991) 2.58
Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med (1972) 2.42
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Protective antibody to endotoxin core: the emperor's new clothes? J Infect Dis (1988) 1.65
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis (1988) 1.32
An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. Q J Med (1987) 1.31
Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis (1988) 1.13
Multiple organ damage caused by tumor necrosis factor and prevented by prior neutrophil depletion. Chest (1989) 1.01
Antibiotic-induced endotoxin release. Lancet (1985) 1.01
Bacterial lipopolysaccharides: relationship of structure and conformation to endotoxic activity, serological specificity and biological function. Adv Exp Med Biol (1990) 1.00
Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. J Infect Dis (1987) 0.97
Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest (1991) 0.93
Endotoxaemia as a cause of fever in immunosuppressed patients. J Clin Pathol (1984) 0.91
Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers. Arch Dis Child (1990) 0.90
Endotoxin levels in immunocompromised children with fever. J Pediatr (1986) 0.88
The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants. J Infect Dis (1989) 0.87
Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant (1992) 0.84
Antibody immunotherapy of gram-negative bacterial sepsis in an immunosuppressed animal model. Transplantation (1988) 0.84
Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia. Schweiz Med Wochenschr Suppl (1983) 0.83
A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia. J Infect Dis (1990) 0.82
Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin. Clin Exp Immunol (1989) 0.82
Endotoxaemia in neutropenic patients. Lancet (1988) 0.81
Plasma endotoxin: increased levels in neutropenic patients do not correlate with fever. J Infect Dis (1989) 0.78
[Preventive treatment of infection caused by gram-negative bacteria using anti-lipopolysaccharide antibodies. Evaluation in patients with aplasia]. Presse Med (1989) 0.78
Endotoxin causes neutrophil-independent oxidative stress in rats. J Appl Physiol (1985) (1988) 0.78
[Properties and efficacy of a human immunoglobulin M preparation for intravenous administration]. Arzneimittelforschung (1985) 0.78
Mechanics of the circulation during cardiopulmonary resuscitation. Pathophysiology and techniques (Part II). Intensive Care Med (1990) 0.77
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med (1991) 2.58
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol (1997) 1.71
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia (2008) 1.62
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer (2001) 1.53
A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 1.52
[Ethics in medicine: needs and forms]. Internist (Berl) (1999) 1.51
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41
[Paraneoplastic syndromes]. Internist (Berl) (1994) 1.40
Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol (1993) 1.40
Role of endotoxin in the pathogenesis of critical illness polyneuropathy. J Neurol (2008) 1.39
Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol (2003) 1.36
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer (2001) 1.32
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia (2005) 1.32
Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones (2000) 1.28
Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer (1994) 1.27
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Management of acute myeloid leukemia in elderly patients. J Clin Oncol (1999) 1.25
Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol (2001) 1.25
Voltage-dependent block of neuronal and skeletal muscle sodium channels by thymol and menthol. Eur J Anaesthesiol (2002) 1.22
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol (2001) 1.21
Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood (1995) 1.20
Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand J Immunol (1978) 1.19
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia (2007) 1.18
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia (2000) 1.18
Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood (2001) 1.17
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol (1985) 1.12
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia (2005) 1.12
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia (2005) 1.09
Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci U S A (1987) 1.09
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol (1997) 1.09
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia (2009) 1.07
Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells. Ann Hematol (1998) 1.07
[Allogeneic transplantation in malignant lymphoma]. Dtsch Med Wochenschr (2001) 1.06
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant (2008) 1.05
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
A PEG-precipitation laser nephelometer technique for detection and characterization of circulating immune complexes in human sera. J Immunol Methods (1982) 1.03
Identification of two novel, kinase-deficient variants of discoidin domain receptor 1: differential expression in human colon cancer cell lines. FASEB J (2001) 1.02
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol (2006) 1.02
Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol (1997) 1.01
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia (2004) 1.01
Trastuzumab and breast cancer. N Engl J Med (2001) 1.01
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol (2001) 1.00
dic(9;20): a new recurrent chromosome abnormality in adult acute lymphoblastic leukemia. Genes Chromosomes Cancer (1995) 1.00
In vitro immunoglobulin production by peripheral blood mononuclear cells from multiple myeloma patients and patients with benign monoclonal gammopathy. Regulation by cell subsets. Scand J Immunol (1984) 1.00
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer (1993) 0.99
Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood (1995) 0.99
Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta. Anticancer Drugs (1996) 0.99
Differential pattern of DNA-aneuploidy in human malignancies. Pathol Res Pract (1985) 0.99
Idiotype-bearing peripheral blood lymphocytes in human multiple myeloma and Waldenström's macroglobulinaemia. Scand J Immunol (1980) 0.99
DNA stemline heterogeneity in colorectal cancer. Cancer (1986) 0.98
Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination. Oncogene (2006) 0.98
Molecular cloning and characterization of a German HIV-1 isolate. AIDS Res Hum Retroviruses (1990) 0.97
[Pathogenesis and biology of leukemias]. Internist (Berl) (2002) 0.97
Multiparameter flow cytometric analysis of human fetal bone marrow B cells. Leukemia (1990) 0.97
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia (2011) 0.96
Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood (1998) 0.96
[Therapeutic strategies in acute myeloid leukemia]. Internist (Berl) (2002) 0.95
Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab Invest (1999) 0.95
Characterization of clone-specific rearrangement T-cell receptor gamma-chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing. Blood (1994) 0.95
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer (2001) 0.95
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia (2002) 0.94
The long-term psychosocial effects of haematopoetic stem cell transplantation. Eur J Cancer Care (Engl) (2003) 0.94
The interferon-induced Mx-homologous protein in people with symptomatic HIV-1 infection. AIDS (1990) 0.94
An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas (2001) 0.94
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia (2009) 0.93